Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Seres Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Seres Therapeutics, Inc.’s stock price such as:

• Seres Therapeutics, Inc.’s current stock price and volume
• Why Seres Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for MCRB from analysts
• MCRB’s stock price momentum as measured by its relative strength

About Seres Therapeutics, Inc. (MCRB)

Before we jump into Seres Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Seres Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Seres Therapeutics, Inc..

Seres Therapeutics, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, Seres Therapeutics, Inc.’s stock price was $16.870.

Seres Therapeutics, Inc. is down 0.3% from its previous closing price of $16.920.

During the last market session, Seres Therapeutics, Inc.’s stock traded between $16.510 and $17.270. Currently, there are approximately 8.76 million shares outstanding for Seres Therapeutics, Inc..

Seres Therapeutics, Inc.’s price-earnings (P/E) ratio is currently at 27.3, which is high compared to the Biotechnology industry median of 19.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Seres Therapeutics, Inc. Stock Price History

Seres Therapeutics, Inc.’s (MCRB) price is currently up 4.78% so far this month.

During the month of November, Seres Therapeutics, Inc.’s stock price has reached a high of $29.980 and a low of $12.476.

Over the last year, Seres Therapeutics, Inc. has hit prices as high as $29.980 and as low as $6.530. Year to date, Seres Therapeutics, Inc.’s stock is up 1.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Seres Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there were 0 analysts who downgraded Seres Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Seres Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Seres Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Seres Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Seres Therapeutics, Inc. (MCRB) by visiting AAII Stock Evaluator.

Relative Price Strength of Seres Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Seres Therapeutics, Inc. has a weighted four-quarter relative price strength of 9.50%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how Seres Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Seres Therapeutics, Inc. Stock Price: Bottom Line

As of November 26, 2025, Seres Therapeutics, Inc.’s stock price is $16.870, which is down 0.3% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Seres Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.